Success Metrics

Clinical Success Rate
84.3%

Based on 555 completed trials

Completion Rate
84%(555/658)
Active Trials
51(6%)
Results Posted
40%(220 trials)
Terminated
103(13%)

Phase Distribution

Ph phase_1
233
29%
Ph phase_2
389
48%
Ph phase_3
130
16%
Ph phase_4
7
1%
Ph not_applicable
36
4%
Ph early_phase_1
6
1%

Phase Distribution

239

Early Stage

389

Mid Stage

137

Late Stage

Phase Distribution801 total trials
Early Phase 1First-in-human
6(0.7%)
Phase 1Safety & dosage
233(29.1%)
Phase 2Efficacy & side effects
389(48.6%)
Phase 3Large-scale testing
130(16.2%)
Phase 4Post-market surveillance
7(0.9%)
N/ANon-phased studies
36(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.0%

555 of 685 finished

Non-Completion Rate

19.0%

130 ended early

Currently Active

51

trials recruiting

Total Trials

806

all time

Status Distribution
Active(56)
Completed(555)
Terminated(130)
Other(65)

Detailed Status

Completed555
Terminated103
unknown64
Recruiting27
Withdrawn27
Active, not recruiting24

Development Timeline

Analytics

Development Status

Total Trials
806
Active
51
Success Rate
84.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (0.7%)
Phase 1233 (29.1%)
Phase 2389 (48.6%)
Phase 3130 (16.2%)
Phase 47 (0.9%)
N/A36 (4.5%)

Trials by Status

completed55569%
not_yet_recruiting40%
unknown648%
suspended10%
recruiting273%
terminated10313%
enrolling_by_invitation10%
withdrawn273%
active_not_recruiting243%

Recent Activity

Clinical Trials (806)

Showing 20 of 806 trialsScroll for more
NCT07224100Phase 2

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting
NCT01624805Phase 2

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Recruiting
NCT02015013Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Recruiting
NCT00083135Phase 1

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Completed
NCT03907488Phase 3

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active Not Recruiting
NCT07012044Phase 1

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Not Yet Recruiting
NCT07257419Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting
NCT00792948Phase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT03220022Phase 1

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Active Not Recruiting
NCT04759586Phase 3

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active Not Recruiting
NCT04959175Phase 1

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting
NCT01553214Phase 4

Improving White Blood Cell Collection From Healthy Donors

Recruiting
NCT06738368Phase 2

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Recruiting
NCT06325709Phase 1

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Recruiting
NCT05436418Phase 1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting
NCT05796570Phase 2

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Recruiting
NCT03214562Phase 1

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
NCT04375631Phase 1

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recruiting
NCT04195633Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting
NCT06942039Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
806